

**Ezetimibe / Atorvastatin Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 04/24/2019  
3.3                09/13/2019                26475-00013            Date of first issue: 10/29/2014

---

**SECTION 1. IDENTIFICATION**

Product name                                : Ezetimibe / Atorvastatin Formulation  
Other means of identification            : No data available

**Manufacturer or supplier's details**

Company name of supplier                : Merck & Co., Inc  
Address                                        : 2000 Galloping Hill Road  
    Kenilworth - New Jersey - U.S.A. 07033  
Telephone                                    : 908-740-4000  
Telefax                                        : 908-735-1496  
Emergency telephone                      : 1-908-423-6000  
E-mail address                               : EHSDATASTEWARD@merck.com

**Recommended use of the chemical and restrictions on use**

Recommended use                          : Pharmaceutical

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS classification in accordance with the Hazardous Products Regulations**

Specific target organ toxicity            : Category 2 (Liver, muscle)  
- repeated exposure (Oral)

**GHS label elements**

Hazard pictograms                        :



Signal Word                                 : Warning

Hazard Statements                        : H373 May cause damage to organs (Liver, muscle) through prolonged or repeated exposure if swallowed.

Precautionary Statements               :  
**Prevention:**  
P260 Do not breathe dust/ fume/ gas/ mist/ vapors/ spray.  
**Response:**  
P314 Get medical advice/ attention if you feel unwell.  
**Disposal:**  
P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards**

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

---

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

## Ezetimibe / Atorvastatin Formulation

Version 3.3      Revision Date: 09/13/2019      SDS Number: 26475-00013      Date of last issue: 04/24/2019  
 Date of first issue: 10/29/2014

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 10 - < 30
Atorvastatin	134523-03-8	>= 10 - < 30
Ezetimibe	163222-33-1	>= 1 - < 5
Magnesium stearate	557-04-0	>= 1 - < 5

Actual concentration or concentration range is withheld as a trade secret

### SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
 Get medical attention if symptoms occur.
- In case of skin contact : Wash with water and soap.  
 Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.  
 Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
 Get medical attention if symptoms occur.  
 Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May cause damage to organs through prolonged or repeated exposure if swallowed.  
 Contact with dust can cause mechanical irritation or drying of the skin.  
 Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray  
 Alcohol-resistant foam  
 Carbon dioxide (CO<sub>2</sub>)  
 Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
 Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
 Nitrogen oxides (NO<sub>x</sub>)  
 Fluorine compounds  
 Metal oxides

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.3	09/13/2019	26475-00013	Date of first issue: 10/29/2014

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions : Discharge into the environment must be avoided.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the

## Ezetimibe / Atorvastatin Formulation

Version 3.3      Revision Date: 09/13/2019      SDS Number: 26475-00013      Date of last issue: 04/24/2019  
 Date of first issue: 10/29/2014

environment.  
 Conditions for safe storage : Keep in properly labeled containers.  
 Store in accordance with the particular national regulations.  
 Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Total dust)	10 mg/m <sup>3</sup>	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m <sup>3</sup>	CA BC OEL
		TWAEV (total dust)	10 mg/m <sup>3</sup>	CA QC OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Atorvastatin	134523-03-8	TWA	0.05 mg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	0.5 mg/100 cm <sup>2</sup>	Internal
Ezetimibe	163222-33-1	TWA	25 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	250 µg/100 cm <sup>2</sup>	Internal
Magnesium stearate	557-04-0	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWA	10 mg/m <sup>3</sup>	CA BC OEL
		TWA (Inhalable fraction)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable fraction)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
 Minimize open handling.

#### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type  
 Hand protection

Material : Chemical-resistant gloves

**Ezetimibe / Atorvastatin Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 04/24/2019  
3.3                09/13/2019              26475-00013            Date of first issue: 10/29/2014

---

Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance	:	powder
Color	:	off-white
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower	:	No data available

**Ezetimibe / Atorvastatin Formulation**

Version 3.3      Revision Date: 09/13/2019      SDS Number: 26475-00013      Date of last issue: 04/24/2019  
Date of first issue: 10/29/2014

---

flammability limit

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)  
Water solubility : 0.01 g/l

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION****Information on likely routes of exposure**

Inhalation  
Skin contact  
Ingestion  
Eye contact

**Ezetimibe / Atorvastatin Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 04/24/2019  
3.3                09/13/2019                26475-00013            Date of first issue: 10/29/2014

---

**Acute toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Acute oral toxicity                                : LD50 (Rat): > 5,000 mg/kg  
  
Acute inhalation toxicity                        : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
  
Acute dermal toxicity                              : LD50 (Rabbit): > 2,000 mg/kg

**Atorvastatin:**

Acute oral toxicity                                : LD50 (Rat, male and female): > 5,000 mg/kg  
  
LD50 (Mouse, male and female): > 5,000 mg/kg

**Ezetimibe:**

Acute oral toxicity                                : LD50 (Rat): > 5,000 mg/kg  
  
LD50 (Mouse): > 5,000 mg/kg  
  
LD50 (Dog): > 3,000 mg/kg  
  
Acute inhalation toxicity                        : Remarks: No data available  
  
Acute dermal toxicity                              : Remarks: No data available  
  
Acute toxicity (other routes of                : LD50 (Rat): > 2,000 mg/kg  
administration)                                    Application Route: Intraperitoneal  
  
LD50 (Mouse): > 1,000 - < 2,000 mg/kg  
Application Route: Intraperitoneal

**Magnesium stearate:**

Acute oral toxicity                                : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials  
  
Acute dermal toxicity                              : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Atorvastatin:**

Species    : Rabbit

**Ezetimibe / Atorvastatin Formulation**

Version 3.3      Revision Date: 09/13/2019      SDS Number: 26475-00013      Date of last issue: 04/24/2019  
Date of first issue: 10/29/2014

---

Result : No skin irritation

**Ezetimibe:**

Species : Rabbit  
Result : No skin irritation

**Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Atorvastatin:**

Species : Rabbit  
Result : No eye irritation  
Method : Draize Test

**Ezetimibe:**

Species : Rabbit  
Result : No eye irritation

**Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Components:****Atorvastatin:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Result : negative

**Ezetimibe:**

Test Type : Maximization Test  
Species : Guinea pig  
Result : negative



## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.3	09/13/2019	26475-00013	Date of first issue: 10/29/2014

---

### Magnesium stearate:

Test Type	:	Maximization Test
Routes of exposure	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative
Remarks	:	Based on data from similar materials

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Cellulose:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Result: negative
		Test Type: In vitro mammalian cell gene mutation test
		Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
		Species: Mouse
		Application Route: Ingestion
		Result: negative

#### Atorvastatin:

Genotoxicity in vitro	:	Test Type: reverse mutation assay
		Test system: Salmonella typhimurium
		Result: negative
		Test Type: reverse mutation assay
		Test system: Escherichia coli
		Result: negative
		Test Type: In vitro mammalian cell gene mutation test
		Test system: Chinese hamster lung cells
		Result: negative
		Test Type: sister chromatid exchange assay
		Test system: Chinese hamster lung cells
		Result: negative
Genotoxicity in vivo	:	Test Type: In vivo micronucleus test
		Species: Mouse
		Cell type: Bone marrow
		Application Route: Oral
		Result: negative
<b>Ezetimibe:</b>		
Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Metabolic activation: with and without metabolic activation
		Result: negative

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.3	09/13/2019	26475-00013	Date of first issue: 10/29/2014

---

Test Type: Chromosomal aberration  
 Test system: Human lymphocytes  
 Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
 Species: Mouse  
 Cell type: Bone marrow  
 Application Route: Oral  
 Result: negative

### Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
 Result: negative  
 Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
 Method: OECD Test Guideline 473  
 Result: negative  
 Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
 Result: negative  
 Remarks: Based on data from similar materials

### Carcinogenicity

Not classified based on available information.

### Components:

#### Cellulose:

Species : Rat  
 Application Route : Ingestion  
 Exposure time : 72 weeks  
 Result : negative

#### Atorvastatin:

Species : Mouse, male and female  
 Application Route : oral (gavage)  
 Exposure time : 2 Years  
 NOAEL : 200 mg/kg body weight  
 LOAEL : 400 mg/kg body weight  
 Result : negative  
 Target Organs : Liver

Species : Rat, female  
 Application Route : oral (gavage)  
 Exposure time : 2 Years  
 LOAEL : 100 mg/kg body weight  
 Target Organs : Musculo-skeletal system

**Ezetimibe / Atorvastatin Formulation**

Version 3.3      Revision Date: 09/13/2019      SDS Number: 26475-00013      Date of last issue: 04/24/2019  
Date of first issue: 10/29/2014

---

**Ezetimibe:**

Species : Rat, female  
Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

Species : Rat, male  
Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

Species : Mouse  
Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

**Reproductive toxicity**

Not classified based on available information.

**Components:****Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Atorvastatin:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, female  
Fertility: NOAEL: 225 mg/kg body weight  
Result: No effects on fertility.

Test Type: Fertility/early embryonic development  
Species: Rat, male  
Fertility: NOAEL: 175 mg/kg body weight  
Result: No effects on fertility.

Effects on fetal development : Species: Rat, female  
Developmental Toxicity: NOAEL: 20 mg/kg body weight  
Result: No teratogenic effects., Embryo-fetal toxicity.  
Remarks: Maternal toxicity observed.

Species: Rabbit, female  
Application Route: Oral  
Developmental Toxicity: NOAEL: 100 mg/kg body weight  
Result: No embryo-fetal toxicity.



**Ezetimibe / Atorvastatin Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 04/24/2019  
3.3                09/13/2019              26475-00013            Date of first issue: 10/29/2014

---

NOAEL                    :    >= 9,000 mg/kg  
Application Route        :    Ingestion  
Exposure time            :    90 Days

**Atorvastatin:**

Species                    :    Rat, male and female  
LOAEL                     :    70 mg/kg  
Application Route        :    oral (gavage)  
Exposure time            :    52 Weeks  
Target Organs             :    Liver

Species                    :    Dog  
LOAEL                     :    10 mg/kg  
Application Route        :    oral (gavage)  
Exposure time            :    104 Weeks  
Target Organs             :    Liver

**Ezetimibe:**

Species                    :    Dog  
NOAEL                     :    1,000 mg/kg  
Application Route        :    Oral  
Exposure time            :    90 d  
Remarks                  :    No significant adverse effects were reported

Species                    :    Rat  
NOAEL                     :    1,500 mg/kg  
Application Route        :    Oral  
Exposure time            :    90 d  
Remarks                  :    No significant adverse effects were reported

Species                    :    Mouse  
NOAEL                     :    500 mg/kg  
Application Route        :    Oral  
Exposure time            :    90 d  
Remarks                  :    No significant adverse effects were reported

Species                    :    Dog  
NOAEL                     :    300 mg/kg  
Application Route        :    Oral  
Exposure time            :    1 y  
Remarks                  :    No significant adverse effects were reported

**Magnesium stearate:**

Species                    :    Rat  
NOAEL                     :    > 100 mg/kg  
Application Route        :    Ingestion  
Exposure time            :    90 Days  
Remarks                  :    Based on data from similar materials

**Aspiration toxicity**

Not classified based on available information.

## Ezetimibe / Atorvastatin Formulation

Version 3.3      Revision Date: 09/13/2019      SDS Number: 26475-00013      Date of last issue: 04/24/2019  
 Date of first issue: 10/29/2014

### Components:

#### **Ezetimibe:**

Not applicable

### **Experience with human exposure**

### Components:

#### **Atorvastatin:**

Ingestion : Symptoms: muscle pain, Fatigue, stomach discomfort, Abdominal pain, constipation, flatulence, liver function change

#### **Ezetimibe:**

Ingestion : Symptoms: Headache, Nausea, Vomiting, Diarrhea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

## SECTION 12. ECOLOGICAL INFORMATION

### **Ecotoxicity**

### Components:

#### **Cellulose:**

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l  
 Exposure time: 48 h  
 Remarks: Based on data from similar materials

#### **Atorvastatin:**

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): > 92 mg/l  
 Exposure time: 96 h  
 Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): 200 mg/l  
 Exposure time: 48 h  
 Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (*Pseudokirchneriella subcapitata* (green algae)): 108 mg/l  
 Exposure time: 72 h  
 Method: OECD Test Guideline 201

NOEC (*Pseudokirchneriella subcapitata* (green algae)): 14 mg/l  
 Exposure time: 72 h  
 Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (*Pimephales promelas* (fathead minnow)): 0.49 mg/l  
 Exposure time: 33 d  
 Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic) : NOEC (*Daphnia magna* (Water flea)): 0.2 mg/l  
 Exposure time: 21 d

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.3	09/13/2019	26475-00013	Date of first issue: 10/29/2014

---

ic toxicity) Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition

### Ezetimibe:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0.125 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 4 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.317 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.317 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.051 mg/l  
Exposure time: 33 d  
Method: OECD Test Guideline 210

NOEC (Cyprinodon variegatus (sheepshead minnow)): 4 mg/l  
Exposure time: 7 d  
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.282 mg/l  
Exposure time: 21 d  
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 4.4 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility.

NOEC: 4.4 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility.

### Magnesium stearate:

**Ezetimibe / Atorvastatin Formulation**

Version 3.3      Revision Date: 09/13/2019      SDS Number: 26475-00013      Date of last issue: 04/24/2019  
Date of first issue: 10/29/2014

---

- Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials
- Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.
- Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.
- NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials
- Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
Exposure time: 16 h  
Test substance: Water Accommodated Fraction  
Remarks: Based on data from similar materials

**Persistence and degradability****Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Atorvastatin:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 7.7 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

**Ezetimibe:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 6.8 %  
Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(4.5 d)  
Method: OECD Test Guideline 111



**Ezetimibe / Atorvastatin Formulation**

Version 3.3      Revision Date: 09/13/2019      SDS Number: 26475-00013      Date of last issue: 04/24/2019  
Date of first issue: 10/29/2014

---

**Magnesium stearate:**

Biodegradability : Result: Not biodegradable.  
Remarks: Based on data from similar materials

**Bioaccumulative potential****Components:****Atorvastatin:**

Partition coefficient: n-octanol/water : log Pow: 1.62

**Ezetimibe:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 173  
Exposure time: 97 d  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.36

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**Mobility in soil****Components:****Atorvastatin:**

Distribution among environmental compartments : log Koc: 2.84

**Ezetimibe:**

Distribution among environmental compartments : log Koc: 4.35  
Method: OECD Test Guideline 106

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3077

---



## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.3	09/13/2019	26475-00013	Date of first issue: 10/29/2014

---

DSL : not determined

IECSC : not determined

---

### SECTION 16. OTHER INFORMATION

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CA AB OEL : Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)

CA BC OEL : Canada. British Columbia OEL

CA QC OEL : Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants

ACGIH / TWA : 8-hour, time-weighted average

CA AB OEL / TWA : 8-hour Occupational exposure limit

CA BC OEL / TWA : 8-hour time weighted average

CA QC OEL / TWAEV : Time-weighted average exposure value

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD

**Ezetimibe / Atorvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
3.3	09/13/2019	26475-00013	Date of first issue: 10/29/2014

---

compile the Material Safety  
Data Sheet

eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 09/13/2019

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8